Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TREACE MEDICAL CONCEPTS, INC. (TMCI)

Treace Medical Q2 revenue falls 4% to $45.4 million; raises revenue outlook

Mixed Impact 4 of 5 earnings Written later

Treace Medical reported second-quarter 2026 revenue of $45.4 million, down 4% from $47.4 million a year earlier, and a net loss of $15.9 million, or $0.24 per share, versus $17.4 million, or $0.28 per share, in the same quarter of 2025. The company raised its full-year 2026 revenue guidance to $204 million to $212 million and narrowed its expected full-year Adjusted EBITDA loss to $3.0 million to $5.0 million.

Key points

  • Q2 2026 revenue was $45.4 million, down 4% from $47.4 million in Q2 2025; gross margin was 78.5% versus 79.7%.
  • Q2 2026 net loss was $15.9 million, or $0.24 per share, compared with $17.4 million, or $0.28 per share, a year earlier.
  • Full-year 2026 revenue guidance rose to $204 million to $212 million from $202 million to $212 million.
  • Full-year 2026 Adjusted EBITDA loss guidance was updated to $3.0 million to $5.0 million from $4.0 million to $6.0 million; cash usage reduction of about 50% was reiterated.

The filing

CompanyTREACE MEDICAL CONCEPTS, INC. (TMCI)
Form8-K, current report
Filed with the SECAug 7, 2026, 7:10 AM ET
Accession number0001630627-26-000017

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.